Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology

home / authors / madelaine-kuiper-np-ucla-santa-monica-hematology-oncology

Articles

Management of Adverse Effects in R/R HER2+ mBC

Management of Adverse Effects in R/R HER2+ mBC

Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology;Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center;Susan Hays, ANP, Washington University Siteman Cancer Center;Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020

Read More

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology;Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center;Susan Hays, ANP, Washington University Siteman Cancer Center;Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020

Read More

HER2-targeted Therapy: Routes of Administration

HER2-targeted Therapy: Routes of Administration

Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology;Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center;Susan Hays, ANP, Washington University Siteman Cancer Center;Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020

Read More

Practical Management of Early Stage HER2+ Breast Cancer

Practical Management of Early Stage HER2+ Breast Cancer

Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology;Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center;Susan Hays, ANP, Washington University Siteman Cancer Center;Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020

Read More

Latest Updated Articles

Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: January 16th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
Published: January 6th 2025 | Updated: January 8th 2025
Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study